CDSCO declines further extension on revised Schedule M for small manufacturers

CDSCO has confirmed that the extended deadline for compliance with the revised Schedule M by small manufacturers will not be extended further, and that units without an approved upgrade plan risk suspension of their manufacturing licences.

What revised Schedule M requires

The revised schedule moves Indian good manufacturing practice substantially closer to WHO GMP, and the additions are structural rather than documentary:

• A pharmaceutical quality system with defined responsibilities
• Quality risk management applied across the product lifecycle
• Computerised system validation, including data integrity controls
• Equipment qualification and process validation protocols
• Change control, deviation management and CAPA with effectiveness checks
• Product quality review conducted annually per product
• Stability testing programme with defined protocols

Why this is capital expenditure

Several of these cannot be met by writing a procedure. Computerised system validation with data integrity controls typically requires replacing or substantially upgrading laboratory instruments and manufacturing execution systems. Environmental monitoring and area classification requirements may require facility modification.

For a small unit, the investment is material relative to turnover, which is precisely why extensions were sought and granted twice.

The position now

CDSCO's order draws a distinction that matters: units that have submitted an upgrade plan and are executing against it will be treated differently from units that have done neither. The relief available is procedural rather than substantive — it buys execution time for those already executing.

Units with no plan filed should assume enforcement.

For larger manufacturers

The deadline applies to small manufacturers; larger units were already required to comply. The read-across is different and worth noting: contract manufacturing arrangements with small units create exposure.

If a small CMO loses its licence in January 2027, your product supply stops and your regulatory filings referencing that site become inaccurate. Marketing authorisation holders should be assessing CMO Schedule M readiness now, as a supply continuity question rather than a quality question.

What Regulens customers see

The revised schedule is decomposed into 340 unit-level obligations. Customers track current state, gap and remediation owner per manufacturing site, and those with contract manufacturing relationships track the same for CMO sites through the vendor attestation workflow.